Clinical trials: psoriasis
Moderate to Severe Plaque Psoriasis
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE CONNECTED (NCT04718896)
- Testing
- bimekizumab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Biopharma SRL
Plaque-Type Psoriasis
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
- Trial name
- NCT00852761
- Testing
- Olux-E Foam, Clobex lotion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Moderate-to-severe Chronic Plaque Psoriasis
Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in Spain.
- Trial name
- PROMISE (NCT01076192)
- Volunteers
- 547 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis.
- Trial name
- UPtimum-PsA (NCT05616871)
- Where
- 89 sites in France, Germany and 2 more
- Volunteers
- 464 people
- Sponsor
- AbbVie
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Moderate to Severe Plaque Psoriasis
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis
- Trial name
- NCT05258331
- Testing
- CT303
- Where
- 3 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- GC Cell Corporation
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while…
- Trial name
- PASI (NCT07545902)
- Testing
- PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- ICIM International S.r.l.
Chronic Stable Plaque Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
- Trial name
- EGALITY (NCT01891864)
- Testing
- GP2015 Etanercept, Enbrel
- Where
- 74 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 531 people
- Sponsor
- Sandoz
Psoriasis
Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test
Ciclosporin is a cyclic nonribosomal polypeptide of 11 amino acids produced by the fungi Tolypocladium inflatum and Cylindrocarpon lucidum.
- Trial name
- NCT00578370
- Testing
- Ciclosporin 0.5% (Formulation 01B), Ciclosporin 1.5% (Formulation 02B), 0.1% betamethasone
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- ISDIN
Psoriasis
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-2 (NCT04862286)
- Testing
- Risankizumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 132 people
- Sponsor
- AbbVie
Moderate to Severe Chronic Plaque Psoriasis
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
- Trial name
- NCT01758705
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Observational Study of Apremilast in Patients With Psoriasis in The Netherlands
This is a multicenter, prospective, non-interventional, observational single arm study. Two-hundred patients will be recruited in the Netherlands over a one year period.
- Trial name
- APRIL (NCT02652494)
- Where
- 12 sites in Netherlands
- Volunteers
- 154 people
- Sponsor
- Amgen
Psoriasis
CT 327 in the Treatment of Psoriasis Vulgaris
This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate psoriasis vulgaris (PV).
- Trial name
- NCT00995969
- Testing
- CT 327
- Where
- 12 sites in United States, Switzerland and 1 more
- Volunteers
- 58 people
- Sponsor
- Creabilis SA
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.
- Trial name
- NCT01077362
- Testing
- ustekinumab 45 mg, ustekinumab 90 mg
- Where
- 80 sites in United States, Austria and 8 more
- Volunteers
- 312 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and…
- Trial name
- ARAVA PASS (NCT06714461)
- Testing
- Leflunomide
- Where
- France
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Sanofi
Psoriasis
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- PHOENIX1 (NCT00267969)
- Testing
- ustekinumab
- Where
- 42 sites in United States, Belgium and 1 more
- Volunteers
- 766 people
- Sponsor
- Centocor Research & Development, Inc.
Psoriasis Vulgaris
Vasoconstriction Trial With LEO 90100 Aerosol Foam
Vasoconstriction study with LEO 90100
- Trial name
- NCT02973776
- Testing
- LEO 90100 aerosol foam, Dermoval®/Dermovate®, Diprosone
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis
A Study of QY101 Ointment in Subjects With Plaque Psoriasis
The goal of this clinical trial is to evaluate the effectiveness of QY101 ointment in adult patients with plaque psoriasis (2-20% BSA).
- Trial name
- NCT06170840
- Where
- China
- Volunteers
- 160 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.